Marcel M. Verbeek

Active 1994–2024

152
Papers
18,467
Citations
84
h-index
147
i10-index

Citations

Citations per year for Marcel M. Verbeek1994: 2 citations1995: 2 citations1996: 6 citations1997: 8 citations1998: 13 citations1999: 13 citations2000: 11 citations2001: 18 citations2002: 12 citations2003: 27 citations2004: 39 citations2005: 35 citations2006: 59 citations2007: 75 citations2008: 72 citations2009: 103 citations2010: 125 citations2011: 157 citations2012: 170 citations2013: 205 citations2014: 263 citations2015: 230 citations2016: 214 citations2017: 221 citations2018: 240 citations2019: 744 citations2020: 870 citations2021: 815 citations2022: 688 citations2023: 524 citations2024: 823 citations2025: 442 citations2026: 10 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,245 citing papers, 19.7% of this breakdownUnited Kingdom: 1,088 citing papers, 9.6% of this breakdownGermany: 778 citing papers, 6.8% of this breakdownSweden: 698 citing papers, 6.1% of this breakdownNetherlands: 687 citing papers, 6% of this breakdownItaly: 639 citing papers, 5.6% of this breakdownChina: 620 citing papers, 5.5% of this breakdownFrance: 421 citing papers, 3.7% of this breakdownSpain: 407 citing papers, 3.6% of this breakdownCanada: 384 citing papers, 3.4% of this breakdownAustralia: 296 citing papers, 2.6% of this breakdownSwitzerland: 288 citing papers, 2.5% of this breakdown
0%19.7%Other 24.9%

Fields

  • Medicine65.5%
  • Biochemistry, Genetics and Molecular Biology16.8%
  • Neuroscience12.4%
  • Psychology1.6%
  • Immunology and Microbiology1.2%
  • Chemistry0.4%
  • Other2.1%

Topics

  • Alzheimer's disease research and treatments12.7%
  • Dementia and Cognitive Impairment Research7.3%
  • Parkinson's Disease Mechanisms and Treatments4.2%
  • Neuroinflammation and Neurodegeneration Mechanisms2.8%
  • Amyotrophic Lateral Sclerosis Research2.6%
  • Intracerebral and Subarachnoid Hemorrhage Research2.1%
  • Other68.3%

Coauthors

All papers

Open in search
  1. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Jonsson, Ludwig Kappos, Mohsen Khademi, Michael Khalil, Jens Kühle, Mikael Landén, Ville Leinonen, Giancarlo Logroscino, Ching‐Hua Lu, Jan Lycke, Nadia Magdalinou, Andrea Malaspina, Niklas Mattsson, Lieke Meeter, Sanjay R. Mehta, Signe Modvig, Tomas Olsson, Ross W. Paterson, Josué Pérez‐Santiago, Fredrik Piehl, Yolande A.L. Pijnenburg, Okko T. Pyykkö, Óskar Ragnarsson, Julio C. Rojas, Jeppe Romme Christensen, Linda Sandberg, Carole Scherling, Jonathan M. Schott, Finn Sellebjerg, Isabella Laura Simone, Tobias Skillbäck, Morten Stilund, Peter Sundström, Anders Svenningsson, Rosanna Tortelli, Carla Tortorella, Alessandro Trentini, Maria Troiano, Martin R. Turner, John C. van Swieten, Mattias Vågberg, Marcel M. Verbeek, Luisa María Villar, Pieter Jelle Visser, Anders Wallin, Andreas Weiss, Carsten Wikkelsø, Edward J. Wild - JAMA Neurology 2019 cited by 760

  2. Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis

    Authors: , , , , - Alzheimer s & Dementia 2021 cited by 306

  3. Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β-Amyloid 42 in Healthy Middle-Aged Men

    Authors: , , , , , - JAMA Neurology 2014 cited by 427

  4. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Chemistry and Laboratory Medicine (CCLM) 2021 cited by 150

  5. Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion

    Authors: , , , , , , , , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2022 cited by 94

  6. A Practical Guide to Immunoassay Method Validation

    Authors: , , , , , , , , , , , , , , , , , , , , - Frontiers in Neurology 2015 cited by 544

  7. Mechanisms of peripheral levodopa resistance in Parkinson’s disease

    Authors: , , - npj Parkinson s Disease 2022 cited by 113

  8. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2017 cited by 214

  9. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gunilla Johansson, Natalia Ermann, John Q. Trojanowski, Ilker Karaca, Holger Wagner, Patrick Oeckl, Linda van Waalwijk van Doorn, Maria Bjerke, Dimitrios Kapogiannis, H. Bea Kuiperij, Lucia Farotti, Yi Li, Brian A. Gordon, Stéphane Epelbaum, Stephanie J. B. Vos, Catharina J.M. Klijn, William E. Van Nostrand, Carolina Minguillón, Matthias Schmitz, Carla Gallo, Andrea Lopez Mato, Florence Thibaut, Simone Lista, Daniel Alcolea, Henrik Zetterberg, Kaj Blennow, Johannes Kornhuber, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut - The World Journal of Biological Psychiatry 2017 cited by 318

  10. Serum NFL discriminates Parkinson disease from atypical parkinsonisms

    Authors: , , , , , , , - Neurology 2019 cited by 153

  11. α‐Synuclein real‐time quaking‐induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism

    Authors: , , , , , - Annals of Neurology 2019 cited by 145

  12. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ming Lim, G.M.S. Mancini, Adela Della Marina, Loreto Martorell, Joe McMenamin, Marije Meuwissen, Helen Mundy, Nils‐Otto Nilsson, Axel Panzer, Bwee Tien Poll‐The, C. Rauscher, C. M. R. Rouselle, Inger Sandvig, T Scheffner, E. Sheridan, N. B. Simpson, Peter Sýkora, RJ Tomlinson, J Q Trounce, David Webb, Bernhard Weschke, Hans Scheffer, Michèl A.A.P. Willemsen - Brain 2010 cited by 413

  13. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease

    Authors: , , , , , , , , , , , , , , - BMC Neurology 2019 cited by 123

  14. Cerebrospinal fluid amyloid β40 is decreased in cerebral amyloid angiopathy

    Authors: , , , , , - Annals of Neurology 2009 cited by 205

  15. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Infectious Diseases 2018 cited by 113

  16. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury

    Authors: , , , , , , , , , - Neurology 2004 cited by 414

  17. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephan A. Kaeser, Elmar Kaiser, Elisabeth Kapaki, Daniel Kidd, Péter Klivènyi, Cindy Soendersoe Knudsen, Markus P. Kummer, James Lui, Albert Lladó, Piotr Lewczuk, Qiao‐Xin Li, Ralph N. Martins, Colin L. Masters, John C. McAuliffe, Marc Mercken, Abhay Moghekar, José Luís Molinuevo, Thomas J. Montine, William Nowatzke, Richard O’Brien, Markus Otto, George P. Paraskevas, Lucilla Parnetti, Ronald C. Petersen, David Prvulovic, Herman P.M. de Reus, Robert A. Rissman, Elio Scarpini, Alessandro Stefani, Hilkka Soininen, Johannes Schröder, Leslie M. Shaw, Anders Skinningsrud, Brith Skrogstad, Annette Spreer, Leda Leme Talib, Charlotte E. Teunissen, John Q. Trojanowski, Hayrettin Tumani, Robert M. Umek, Bianca Van Broeck, Hugo Vanderstichele, László Vécsei, Marcel M. Verbeek, Manfred Windisch, Jing Zhang, Henrik Zetterberg, Kaj Blennow - Alzheimer s & Dementia 2011 cited by 412

  18. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review

    Authors: , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2018 cited by 126

  19. β-Amyloid in CSF

    Authors: , , , , , , , , , , , - Neurology 2016 cited by 82

  20. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , - Annals of Neurology 2023 cited by 51

  21. The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice

    Authors: , , , , , , , , , - Journal of Neurology Neurosurgery & Psychiatry 2017 cited by 236

  22. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency

    Authors: , , , , , , , , , , , , , , , , , , , - Orphanet Journal of Rare Diseases 2017 cited by 232

  23. Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Oya Kuseyri Hübschmann - Orphanet Journal of Rare Diseases 2020 cited by 151

  24. Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update

    Authors: , , , , , , , , , , , , , , , , , , , - Biomarkers in Medicine 2012 cited by 357